NCT00277069View on ClinicalTrials.gov

Phase I-II Study of Carboplatin, Vinorelbine and Capecitabine in Patients With Metastatic Breast Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

May 31, 2000

Primary Completion Date

March 31, 2005

Study Completion Date

March 31, 2006

Conditions
BreastCancer
Interventions
DRUG

Carboplatin

Carboplatin given at 300mg/m2 IV over 30 minutes day 1, q 21 days

DEVICE

Capecitabine

Capecitabine is administered at 1500mg/m2 PO qd in 2 divided doses day 1-14 q 21 days

DRUG

Vinorelbine

Vinorelbine: 25mg/m2 IV over 10 minutes day 1, 8 q 21 days

Trial Locations (1)

87131

University of New Mexico, Albuquerque

All Listed Sponsors
lead

University of New Mexico

OTHER

NCT00277069 - Phase I-II Study of Carboplatin, Vinorelbine and Capecitabine in Patients With Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter